Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: US79400X4043 (+1 more)
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Optipharm.CO.,LTD Biotech for animal health and xenotransplantation using genetically engineered pig organs.	South Korea	153710
ORGANOIDSCIENCES LTD. Organoid-based platforms for drug testing and regenerative therapeutics.	South Korea	476040
Oricon Inc. Provides entertainment industry data, music charts, web media, and marketing services.	Japan	4800
ORIENTBIO Inc. Provides animal models & technical services for preclinical R&D to pharma & research institutions.	South Korea	002630
Oryzon Genomics S.A. Develops epigenetic-based medicines for cancer and central nervous system disorders.	Spain	ORY
OSCOTECInc. A clinical-stage drug discovery company developing innovative medicines for unmet needs.	South Korea	039200
OSE Immunotherapeutics Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.	France	OSE
Oxurion NV Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.	Belgium	OXUR
PA Co., Ltd Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.	Japan	4766
Passage BIO, Inc. Developing genetic medicines for severe CNS and neurodegenerative disorders.	United States of America	PASG